CureVac (CVAC) to Release Quarterly Earnings on Thursday

CureVac (NASDAQ:CVAC) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 22nd. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $4.27 million for the quarter.

CureVac (NASDAQ:CVAC) last announced its earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $15.44 million for the quarter, compared to analysts’ expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Trading Up 10.6%

CureVac stock opened at $4.28 on Wednesday. The firm has a market capitalization of $960.17 million, a PE ratio of 7.78 and a beta of 2.43. The business’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $3.26. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. CureVac has a 52 week low of $2.37 and a 52 week high of $5.28.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. JMP Securities reiterated a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th. UBS Group decreased their price objective on CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th.

Institutional Trading of CureVac

Several hedge funds have recently added to or reduced their stakes in CVAC. Millennium Management LLC grew its position in CureVac by 10.3% during the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company’s stock worth $5,033,000 after acquiring an additional 169,947 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in CureVac during the 1st quarter worth approximately $142,000. Finally, Integrated Wealth Concepts LLC increased its holdings in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares in the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.